Some patients stop after achieving stability with strong lifestyle habits, while others find continuous or intermittent therapy necessary for long-term weight management
Placing Bets Emerging strategies and modalities signal industry-wide shifts ahead
SURMOUNT-1: Tirzepatide for Obesity The SURMOUNT-1 trial (NEJM, 2022) studied tirzepatide weight loss in 2,539 adults with obesity (without diabetes) over 72 weeks: STEP 1: Semaglutide for Obesity The STEP 1 trial (NEJM, 2021) studied semaglutide 2.4mg in 1,961 adults with obesity (without diabetes) over 68 weeks: Cross-Trial Summary Comparing across trials (with the caveat that indirect comparison has limitations): tirzepatide 15mg produced about 6 percentage points more weight loss than semaglutide 2.4mg over similar timeframes
Chronic alcohol-induced liver injury and oxidant stress are decreased in cytochrome P4502E1 knockout mice and restored in humanized cytochrome P4502E1 knock-in mice
Murata, Effects of antidiabetic drugs on muscle mass in type 2 diabetes mellitus
Fat burners should not be taken during pregnancy, however, and also by people with heart disease and high blood pressure